Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10436302 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL20932872 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| Hydrochloric Acid SCHEMBL23111921 | 0.98 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL1252077 | 0.86 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL7138120 | 0.84 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL28603100 | 0.84 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL25867906 | 0.84 | GABRP (0.33) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL25660617 | 0.81 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1GRIK1 | |
| SCHEMBL15368912 | 0.81 | TSHR (0.35) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 | |
| SCHEMBL14036911 | 0.81 | SLC7A5 (0.34) | SLC7A5SLC1A3SLC1A2SLC1A1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250263365-A1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-21 | — | — | US | disclosed |
| EP-3878836-B1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12312297-B2 | O-substituted serine derivative production method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-05-27 | — | — | US | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-22 | — | — | US | disclosed |
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-04-25 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2012048013-A2 | PHOSPHORODIAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INJECTIONS | INHIBITEX, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
| CN-101098852-A | Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof | SMITHKLINE BEECHAM CORP (US) | 2008-01-02 | — | — | CN | disclosed |
| EP-0353211-A1 | New compounds | Aktiebolaget Hässle (SE) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119322-A1 | PREPARATION OF FUNCTIONAL HOMOCYSTEINE RESIDUES IN POLYPEPTIDES AND PEPTIDES | BHMT2, BHMT, PTMS | SLC7A5 159/4885SLC1A3 707/4885SLC1A2 963/4885 |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | SLC7A5 907/4885SLC1A3 2260/4885SLC1A2 2880/4885 |
| US-20250263365-A1 | O-SUBSTITUTED SERINE DERIVATIVE PRODUCTION METHOD | STS, SMOX, TST | SLC7A5 431/4885SLC1A3 832/4885SLC1A2 1457/4885 |
| US-11732008-B2 | Preparation of functional homocysteine residues in polypeptides and peptides | BHMT2, BHMT, PTMS | SLC7A5 159/4885SLC1A3 707/4885SLC1A2 963/4885 |
| US-12312297-B2 | O-substituted serine derivative production method | STS, SMOX, TST | SLC7A5 431/4885SLC1A3 832/4885SLC1A2 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.